These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11380487)

  • 1. Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis.
    Oleksik A; Duong T; Popp-Snijders C; Pliester N; Asma G; Lips P
    Clin Endocrinol (Oxf); 2001 May; 54(5):575-82. PubMed ID: 11380487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women.
    Boucher A; D'Amour P; Hamel L; Fugère P; Gascon-Barré M; Lepage R; Ste-Marie LG
    J Clin Endocrinol Metab; 1989 Apr; 68(4):831-6. PubMed ID: 2921312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carotid artery intima-media thickness after raloxifene treatment.
    Mack WJ; Dhungana B; Dowsett SA; Keech CA; Feng M; Li Y; Hodis HN
    J Womens Health (Larchmt); 2007 Apr; 16(3):370-8. PubMed ID: 17439382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
    JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
    Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
    JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes.
    Palomba S; Numis FG; Mossetti G; Rendina D; Vuotto P; Russo T; Zullo F; Nappi C; Nunziata V
    Hum Reprod; 2003 Jan; 18(1):192-8. PubMed ID: 12525466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
    Barrett-Connor E; Ensrud KE; Harper K; Mason TM; Sashegyi A; Krueger KA; Anderson PW
    Clin Ther; 2003 Mar; 25(3):919-30. PubMed ID: 12852708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
    Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
    JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
    Maricic M; Adachi JD; Sarkar S; Wu W; Wong M; Harper KD
    Arch Intern Med; 2002 May; 162(10):1140-3. PubMed ID: 12020184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis.
    Sahota O; Mundey MK; San P; Godber IM; Lawson N; Hosking DJ
    Bone; 2004 Jul; 35(1):312-9. PubMed ID: 15207772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate dependence of acute PTH release and association between basal plasma calcium and set point of calcium-PTH curve in dialysis patients.
    De Cristofaro V; Colturi C; Masa A; Comelli M; Pedrini LA
    Nephrol Dial Transplant; 2001 Jun; 16(6):1214-21. PubMed ID: 11390723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
    Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
    Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
    Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
    J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.